Atherosclerosis of retinal arteries in men: Role of serum lipoproteins and apoproteins

Croatian Medical Journal

Volumn 45, Issue 3, 2004, Pages 333-337

  Tedeschi Reiner, Eugenia ^a   Reiner, Željko ^b   Sonicki, Zdenko ^c  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Apoproteins; Arteriosclerosis; Cholesterol; Lipoproteins; Retina; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; RETINA ARTERY; RETINA BLOOD VESSEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOPROTEINS; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; RETINAL ARTERY; RISK FACTORS;

EID: 2642522707     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835-8.
2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease. BMJ. 1994;308:367-72.
3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
4. Keys A. Seven Countries: a multivariate analysis of death and coronary heart disease. Cambridge (MA): Harvard University Press; 1980.
5. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-98.
6. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8:207-11.
7. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J. 1998;19 Suppl A:A2-11.
8. Austin MA. Triacylglycerol and coronary heart disease. Proc Nutr Soc. 1997;56:667-70.
9. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-36.
10. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-85.
11. Barbir M, Wile D, Trayner I, Aber VR, Thompson GR. High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease. Br Heart J. 1988;60:397-403.
12. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995; 346:1647-53.
13. Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, et al. Lipids and stroke: a paradox resolved. Arch Neurol. 1996;53:303-8.
14. Reiner Ž, Čulinović R, Šoša T, Tedeschi-Reiner E. Endogenous hormones and serum lipoproteins in arteriosclerosis obliterans of lower extremities. In: Proceedings of the 9th International Symposium on Atherosclerosis; 1991 Oct 6-11; Rosemont, IL, USA. p. 204.
15. Vigna GB, Bolzan M, Romagnoni F, Valerio G, Vitale E, Zuliani G, et al. Lipids and other risk factors selected by discriminant analysis in symptomatic patients with supra-aortic and peripheral atherosclerosis. Circulation. 1992;85:2205-11.
16. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb. 1993;13:1441-8.
17. Scheie HG. Evaluation of ophthalmoscopic changes of hypertension and arteriolar sclerosis. Ama Arch Ophtalmol. 1953;49:117-38.
18. Scheie HG, Albert DM. Textbook of ophthalmology. Philadelphia (PA): WB Saunders; 1977.
19. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11: 583-95.
20. Wieland H, Seidel D. A simple specific method for precipitation of low density lipoproteins. J Lipid Res. 1983;24:904-9.
21. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982;23:1206-23.
22. Alaupović P. Determination of plasma apoprotein profiles. In: Schettler G, Gotto AM, editors. Atherosclerosis VI. Heidelberg-Berlin-New York: Springer; 1982. p. 516-21.
23. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40:819-25.
24. Sautter H. "Early atherosclerotic syndrom" of the eye [in German]. Ber Dtsch Ges Ophtalmol. 1964;65:379-4.
25. Utermann D, Klempien EJ. On the relationships between the symptoms of arteriosclerosis on the fundus oculi and the degenerative diseases of the general vascular system. A biochemical and clinical-statistical study [in German]. Doc Ophthalmol. 1968;24:201-74.
26. Utermann D. Arteriosclerosis of the eye. What the internist should know [in German]. Internist (Berl). 1987; 28:357-65.
27. Hogan MJ, Feeney L. The ultrastructure of the retinal blood vessels. I. The large vessels. J Ultrastruct Res. 1963;39:10-28.
28. Mausolf FA, editor. The eye and systemic disease. London: Mosby; 1980.
29. Hogan MJ, Feeney L. The ultrastructure of the retinal vessels. II. The small vessels. J Ultrastruct Res. 1963;49: 29-46.
30. Hogan MJ, Alvorado JA, Weddell JA. Histology of the human eye. Philadelphia-London-Toronto: WB Saunders; 1971.
31. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274:131-6.
32. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ. 1994;309:11-5.
33. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease. N Engl J Med. 1982;306:1513-9.
34. Karathanasis S. Lipoprotein metabolism. High density lipoproteins. In: Lusis AJ, Rotter JJ, Sparkes RS, editors. Molecular genetics of coronary artery disease: candidate genes and processes in atherosclerosis. Basel: Karger; 1993. p. 140-71.
35. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-72.
36. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-4.
37. Fruchart JC, De Geteire C, Delfly B, Castro GR. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis. 1994;110 Suppl:S35-9.
38. Hertzer NR. Basic data concerning associated coronary disease in peripheral vascular patients. Ann Vasc Surg. 1987;1:616-20.